ANDA 65307, held by Chartwell Rx. Cefadroxil/Cefadroxil Hemihydrate.
As of Nov 16, 2026, ANDA 65307 (Cefadroxil), held by Chartwell Rx, was first approved by FDA on Oct 16, 2006, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 16, 2006 | Original application | Approved | None posted |
| CefadroxilEQ 250MG BASE/5ML · for suspension;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
| CefadroxilEQ 500MG BASE/5ML · for suspension;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
| Nov 17, 2008 | Supplement 3Labeling | Approved | None posted |
| Aug 18, 2008 | Supplement 2Labeling | Approved | None posted |
| Feb 25, 2008 | Supplement 1Labeling | Approved | None posted |
| Oct 16, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters